• Publications
  • Influence
European S3‐Guidelines on the systemic treatment of psoriasis vulgaris
TLDR
Phototherapy represents a safe and very effective treatment option for moderate to severe forms of psoriasis vulgaris and has a good cost-benefit ratio, but the potentially significant costs for, and time required of, the patient must be considered.
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
TLDR
The efficacy of ustekinumab at a dose of 45 or 90 mg was superior to that of high-dose etanercept over a 12-week period in patients with psoriasis.
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
TLDR
Bdalumab significantly improved plaque psoriasis in this 12-week, phase 2 study and was superior to placebo in all comparisons.
Genomewide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways
TLDR
The results provide strong support for the association of at least seven genetic loci and psoriasis (each with combined P < 5 × 10−8) and suggest priority targets for study in other auto-immune disorders.
...
...